ImmuPharma Puts On Very Brave Face After Lupus Drug Flop
Shares in the UK biotech have fallen through the floor following a failed Phase III trial of Lupuzor but ImmuPharma remains surprisingly upbeat about the lupus drug's prospects.
Shares in the UK biotech have fallen through the floor following a failed Phase III trial of Lupuzor but ImmuPharma remains surprisingly upbeat about the lupus drug's prospects.